Next Up Fiscal 2024 1Q Financial Results Quarterly Highlights Emily Leproust Chief Executive Officer Q&A Session Legal Disclaimers | PROPRIETARY and CONFIDENTIAL | TWIST BIOSCIENCE $77.5 M Orders Strong orders 4 1Q 2024 • Launch of Express Genes* ü FoF-enabled new product introduction 450bp oligo synthesis *Limited launch initiated November 13, 2023; full launch on January 24, 2024 ü RNA sequencing workflow Advanced library prep Growth Combined Biopharma Business Including Historical Abveris Programs | TWIS ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. " We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Washington, D.C. 20549 Twist Bioscience Corporation FORM 10-Q (Mark One) (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround starting at five business days1, to include larger DNA preparations up to 1 milligram. The Express Genes offering, initially launched in November 2023, now extends to larger ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to d ...

Financial Performance - The company incurred net losses of $204.6 million, $217.9 million, and $152.1 million for the years ended September 30, 2023, 2022, and 2021, respectively, with an accumulated deficit of $1,033.0 million as of September 30, 2023[142]. - The net loss attributable to common stockholders for 2023 was $204.6 million, compared to a net loss of $217.9 million in 2022, indicating a 6.0% improvement[438]. - The accumulated deficit increased to $1.033 billion as of September 30, 2023, compared to $828.4 million in 2022, reflecting a 24.7% increase[436]. - The company generated cash flows from operating activities amounting to a net cash used of $142.5 million, compared to $124.4 million in the previous year[446]. - Cash and cash equivalents decreased to $286.5 million as of September 30, 2023, down from $378.7 million in the previous year, representing a decline of 24.3%[436]. - The company's total operating expenses for 2023 were $462.3 million, up from $438.3 million in 2022, reflecting a 5.5% increase[438]. - The company reported interest income of $14.4 million in 2023, significantly higher than $3.1 million in 2022, marking a 370.6% increase[438]. - Twist Bioscience's total stockholders' equity decreased to $623.4 million in 2023 from $789.4 million in 2022, a decline of 21.0%[436]. - The company incurred stock-based compensation expenses of $30.3 million in 2023, down from $79.7 million in 2022[446]. - The company reported a net cash provided by investing activities of $50.6 million, a significant recovery from a net cash used of $232.9 million in the previous year[446]. Operational Challenges - The company expects to incur substantial losses and negative cash flow for the foreseeable future, influenced by factors such as market acceptance of products and inflationary pressures[142]. - A strategic restructuring plan announced on May 5, 2023, included a reduction in force affecting approximately 270 employees worldwide, which may not yield anticipated savings and could disrupt operations[147]. - The company relies on a single-source supplier for a critical component in its DNA synthesis process, and any disruption could adversely affect manufacturing capacity and revenue[142]. - The company faces challenges in expanding its DNA synthesis manufacturing capacity, which could impact revenue growth if customer demand increases[181]. - Any delays in securing raw materials or components could adversely affect production capabilities and financial performance[190]. - The company relies on third-party suppliers for critical components, which poses risks to its operational capabilities[454]. - The company is heavily reliant on the success of its synthetic DNA products, which have generated substantially all of its revenue to date[183]. - The company has invested significantly in research and development for synthetic DNA products, indicating a capital-intensive business model[182]. Market and Competitive Landscape - The company operates in a highly competitive industry with numerous competitors, which may lead to pricing pressures and adversely affect sales and profitability[206]. - The company’s business model is based on being the only provider of DNA synthesis on a silicon chip at a large commercial level, which could be disrupted if competitors develop similar technologies[167]. - The company’s revenue growth may depend on leveraging its DNA synthesis platform in adjacent markets, such as pharmaceutical biologics and digital data storage[170]. - A significant portion of the company’s sales depends on customers' research and development budgets, which can be subject to unexpected variations[171]. - The company generally does not have long-term contracts with customers, making it difficult to predict purchasing behavior[175]. - The loss of significant customers could adversely affect revenue and market reputation, as a substantial portion of revenue comes from a limited number of large customers[195]. Regulatory and Compliance Risks - The company is subject to the U.S. Foreign Corrupt Practices Act and the UK Anti-Bribery Act, which could result in civil or criminal penalties if violated, adversely affecting financial condition and growth prospects[201]. - The company is subject to strict regulatory controls on product exports, which could delay shipments and adversely affect revenues and profitability[215]. - The FDA's proposed rule on laboratory-developed tests could increase regulatory requirements, potentially influencing product sales and customer usage[217]. - Future products may be subject to additional FDA regulation, which could impose restrictions on marketing and sales, adversely affecting business operations[218]. - The company may incur significant costs to comply with the European Union's In Vitro Diagnostic Device Regulation (IVDR), which could adversely affect its business in the EU[219]. - The uncertainty from Brexit continues to pose risks that could adversely impact the company’s business and financial condition[178]. Intellectual Property and Legal Risks - The company’s ability to protect its intellectual property is uncertain, and failure to maintain such protection could adversely affect its competitive position[142]. - The company has faced challenges with patent applications, including an opposition to its European Patent No. 3030682 related to polynucleotide synthesis, which was initially decided to be revoked[243]. - Legal proceedings to enforce patent rights can be costly and time-consuming, potentially impacting the company's ability to market its products[256]. - The company may incur substantial costs related to royalty payments for licenses if it is found to infringe on third-party patents, negatively affecting gross margins[259]. - The complexity of collaboration arrangements may hinder the establishment of favorable agreements for licensing third-party intellectual property rights[265]. - The company may struggle to obtain necessary rights to products and technologies through acquisitions and in-licenses, impacting growth[264]. Future Outlook and Strategic Initiatives - The company plans to continue expanding its production capabilities and enter new markets, including COVID-19 testing products and pharmaceutical biologics drug discovery[143]. - The company aims to attract new customers and retain existing ones by delivering high-quality products and effective technical support, which is critical for growth[154]. - The company is pursuing strategic acquisitions to expand its product offerings in local and international markets, but faces risks associated with integration and financial resources[199]. - The company’s future success relies on its ability to develop and manufacture new products in the rapidly changing synthetic biology industry[165]. - The company may consider strategic transactions, including collaborations or investments, but faces significant operational and financial risks associated with such activities[200]. Cybersecurity and Operational Risks - The company has not experienced any material system failure or security breach to date, but ongoing cybersecurity threats could materially disrupt operations and financial condition[157]. - The company is at heightened risk of cyber attacks due to political uncertainty related to Russia's invasion of Ukraine, which could affect technology, data, and intellectual property[159]. - The company is vulnerable to natural disasters and public health crises that could disrupt operations and impair critical systems[223]. Stock and Market Risks - The market price of the company's common stock is likely to be volatile, influenced by various external factors beyond its control[285]. - The company has never paid dividends and does not intend to do so in the foreseeable future, relying on stock price appreciation for investor returns[275]. - Future sales and issuances of common stock could result in additional dilution for existing stockholders and potentially cause the stock price to decline[291]. - The company has been and may continue to be the target of short selling strategies that could drive down its stock price[290]. - The company's charter documents may prevent favorable takeover attempts, potentially reducing stock market value[276].

Twist Bioscience Corporation (NASDAQ:TWST) Q4 2023 Results Conference Call November 17, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and Chief ESG Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - Acting CFO Conference Call Participants Luke Sergott - Barclays Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Catherine Schulte - Baird Steven Mah - TD Cowen Sung-Ji Nam - Scotiabank Madeline Mollman - William Blair Operator Welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Twist Bioscience Corporation (NASDAQ:TWST) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Luke Sergott - Barclays Steven Mah - TD Cowen Catherine Schulte - Baird Rachel Vatnsdal - JP Morgan Matt Larew - William Blair Sung-Ji Nam - Scotiabank Operator ...

ACTACCATCAT Financial Results . BIOSCIENCE Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Q&A Session T This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act o ...